Lung - Research Protocols

Alliance A081801:

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center

Alliance A151216:

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center
 

ECOG E4512:

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs. Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center

LUNGMAP:

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center

KEYNOTE-867:

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-347) in Participants with Medically Inoperable Stages I or IIA NSCLC
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center

Alliance A171901:

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist’s/Patients Choice)
LifeBridge Health Sites: Sinai Hospital of Baltimore, Northwest Hospital, William E Kahlert Regional Cancer Center



For more information about ongoing clinical trials at the Alvin & Lois Lapidus Cancer Institute, please contact the oncology research team at 410-601-6120